TP53 and pancreatic neoplasm: This work is in line with recent papers demonstrating convergent evolutionary trajectories in murine and human pancreatic cancers, where the spontaneous loss of CDKN2A/B, TP53 and SMAD4 represents a constrained route to malignant progression30,31.